ACRV
Acrivon Therapeutics, Inc.
$1.48
+2.78%
$63.3M
No data for this timeframe.
Vol
Market Cap$63.3M
Cap SizeMicro Cap
Inst. Holders23 funds
Inst. Value$17.0M
Inst. Activity2 buys / 0 sells
Reddit Sentiment60° Warm
SEC Reports2
Press Releases1
Recent Activity
Jun 5, 2026
SEC
Acrivon Therapeutics filed a DEFA14A supplementing its definitive proxy for the June 17, 2026 Annual Meeting, adding a n
DEFA14A — Impact 3/10
May 21, 2026
Insider
Blume-Jensen Peter surrendered for taxes 13,729 shares
President and CEO @ $1.79 ($24.6K)
May 20, 2026
earnings_calendar
ACRV Q1 2026 Earnings Scheduled — 2026-05-20
May 18, 2026
Insider
Blume-Jensen Peter was granted 180,095 shares
President and CEO
May 18, 2026
Insider
Devroe Eric was granted 72,981 shares
Chief Operating Officer
Apr 30, 2026
SEC
Acrivon Therapeutics filed a DEFA14A (definitive additional proxy soliciting materials) for its upcoming Annual Meeting
DEFA14A — Impact 2/10
Inst.
Marex Group plc — DOUBLED
20,000 shares ($27.8K)
Inst.
FEDERATED HERMES, INC. — ADD
7,924 shares ($11.0K)
Price Targets
Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$11.50 (Jan 2026)
Current $1.48
Low $7.00
Median $10.50
High $19.00
6 analysts
$7.00
$19.00
Analyst Ratings
4Strong Buy
9Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jan 9, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.50 ▲ +9.1% | $-0.55 — $-0.44 | 10% YoY | 7 |
| Next Q | $-0.52 ▼ -0.6% | $-0.59 — $-0.49 | -11% YoY | 7 |
| Current FY | $-2.07 | $-2.50 — $-1.68 | -2% YoY | 7 |
| Next FY | $-1.95 ▼ -4.8% | $-2.61 — $-1.11 | 6% YoY | 7 |
Latest Reports
NEUTRAL
DEFA14A
3/10
Acrivon Therapeutics filed a DEFA14A supplementing its definitive proxy for the June 17, 2026 Annual Meeting, adding a n
Jun 5, 2026
NEUTRAL
DEFA14A
2/10
Acrivon Therapeutics filed a DEFA14A (definitive additional proxy soliciting materials) for its upcoming Annual Meeting
Apr 30, 2026
BULLISH
Press
8/10
Acrivon Therapeutics reported financial results for Q4 and full year 2025, showing reduced net losses compared to the pr
Mar 19, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | NEAR_EXIT |
| RA CAPITAL MANAGEMENT, L.P. | $11.6M | — |
| WELLINGTON MANAGEMENT GROUP LLP | $1.2M | — |
| RENAISSANCE TECHNOLOGIES LLC | $1.1M | DOUBLED |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.0M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 21, 2026 | Blume-Jensen Peter | F | $24.6K |
| May 18, 2026 | Blume-Jensen Peter | A | $0.00 |
| May 18, 2026 | Devroe Eric | A | $0.00 |
| May 18, 2026 | Gamelin Erick | A | $0.00 |
| May 18, 2026 | Levy Adam | A | $0.00 |
Reddit Sentiment
60°
Warm
Bearish
Neutral
Bullish
23 institutional holders with $17.0M total value (12,214,490 shares) as of 2026-Q1. Top holders: ROYAL, RA, WELLINGTON. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 25 | $0.00 | 0.0% | NEAR_EXIT -96.3% |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 8,340,508 | $11.6M | 68.3% | — |
| 3 | WELLINGTON MANAGEMENT GROUP LLP | 888,130 | $1.2M | 7.3% | — |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 758,440 | $1.1M | 6.2% | DOUBLED +877.5% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 722,035 | $1.0M | 5.9% | — |
| 6 | MARSHALL WACE, LLP | 560,436 | $779.0K | 4.6% | DOUBLED +231.4% |
| 7 | TWO SIGMA INVESTMENTS, LP | 389,395 | $541.3K | 3.2% | ADD +83.3% |
| 8 | BlackRock, Inc. | 208,939 | $290.4K | 1.7% | TRIM -38.0% |
| 9 | VANGUARD FIDUCIARY TRUST CO | 107,529 | $149.5K | 0.9% | — |
| 10 | STATE STREET CORP | 67,145 | $93.3K | 0.5% | TRIM -71.1% |
| 11 | MORGAN STANLEY | 36,671 | $51.0K | 0.3% | DOUBLED +108.2% |
| 12 | PANAGORA ASSET MANAGEMENT INC | 33,814 | $47.0K | 0.3% | — |
| 13 | Marex Group plc | 20,000 | $27.8K | 0.2% | DOUBLED +100.0% |
| 14 | DIMENSIONAL FUND ADVISORS LP | 18,364 | $25.4K | 0.1% | TRIM -49.7% |
| 15 | BANK OF AMERICA CORP /DE/ | 16,513 | $23.0K | 0.1% | — |
| 16 | GOLDMAN SACHS GROUP INC | 14,742 | $20.5K | 0.1% | — |
| 17 | FMR LLC | 9,422 | $13.1K | 0.1% | ADD +56.6% |
| 18 | FEDERATED HERMES, INC. | 7,924 | $11.0K | 0.1% | ADD +41.2% |
| 19 | BARCLAYS PLC | 5,940 | $8.3K | 0.0% | TRIM -36.0% |
| 20 | Vanguard Global Advisers, LLC | 4,453 | $6.2K | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Marex Group plc | DOUBLED | 10,000 | 20,000 | +100.0% | $27.8K | 2026-Q1 |
| FEDERATED HERMES, INC. | ADD | 5,612 | 7,924 | +41.2% | $11.0K | 2026-Q1 |
| TWO SIGMA INVESTMENTS, LP | ADD | 319,205 | 585,069 | +83.3% | $1.4M | 2025-Q4 |
| MARSHALL WACE, LLP | DOUBLED | 149,715 | 496,081 | +231.4% | $1.2M | 2025-Q4 |
| BlackRock, Inc. | TRIM | 330,957 | 205,124 | -38.0% | $494.3K | 2025-Q4 |
| FEDERATED HERMES, INC. | DOUBLED | 2,426 | 5,612 | +131.3% | $13.5K | 2025-Q4 |
| CWM, LLC | NEAR_EXIT | 790 | 127 | -83.9% | — | 2025-Q3 |
| UBS Group AG | DOUBLED | 455 | 683,218 | +150057.8% | $1.2M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 181,172 | 319,205 | +76.2% | $577.8K | 2025-Q3 |
| ROYAL BANK OF CANADA | NEAR_EXIT | 849 | 31 | -96.3% | — | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 52,100 | 509,295 | +877.5% | $606.1K | 2025-Q2 |
| MARSHALL WACE, LLP | TRIM | 450,391 | 181,187 | -59.8% | $215.6K | 2025-Q2 |
| STATE STREET CORP | TRIM | 232,551 | 67,145 | -71.1% | $79.9K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | TRIM | 111,320 | 63,636 | -42.8% | $75.7K | 2025-Q2 |
| DIMENSIONAL FUND ADVISORS LP | TRIM | 44,154 | 22,204 | -49.7% | $26.4K | 2025-Q2 |
| NISA INVESTMENT ADVISORS, LLC | TRIM | 959 | 584 | -39.1% | $695.00 | 2025-Q2 |
| UBS Group AG | NEAR_EXIT | 12,888 | 455 | -96.5% | $541.00 | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 7,090 | 141 | -98.0% | $168.00 | 2025-Q2 |
| BARCLAYS PLC | TRIM | 32,698 | 20,925 | -36.0% | $25.00 | 2025-Q2 |
| CWM, LLC | DOUBLED | 49 | 790 | +1512.2% | $1.00 | 2025-Q2 |
| BAKER BROS. ADVISORS LP | TRIM | 52,885 | 22,809 | -56.9% | $46.3K | 2025-Q1 |
| ROYAL BANK OF CANADA | TRIM | 1,638 | 849 | -48.2% | $2.0K | 2025-Q1 |
| NISA INVESTMENT ADVISORS, LLC | DOUBLED | 100 | 959 | +859.0% | $1.9K | 2025-Q1 |
| MARSHALL WACE, LLP | TRIM | 809,859 | 597,794 | -26.2% | $3.6M | 2024-Q4 |
| Trexquant Investment LP | TRIM | 30,383 | 16,871 | -44.5% | $101.6K | 2024-Q4 |
14 unique insiders with 30 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 21, 2026 | Blume-Jensen Peter | President and CEO | TAX W/H | 13,729 | $1.79 | $24.6K |
| May 18, 2026 | Blume-Jensen Peter | President and CEO | AWARD | 180,095 | — | — |
| May 18, 2026 | Devroe Eric | Chief Operating Officer | AWARD | 72,981 | — | — |
| May 18, 2026 | Gamelin Erick | Chief Development Officer | AWARD | 38,584 | — | — |
| May 18, 2026 | Levy Adam D. | Chief Financial Officer | AWARD | 46,167 | — | — |
| May 18, 2026 | Miller Mary | Chief Legal Officer | AWARD | 49,830 | — | — |
| May 18, 2026 | Mirza Mansoor Raza | Chief Medical Officer | AWARD | 38,817 | — | — |
| May 18, 2026 | Peterson Katharine | Chief Accounting Officer | AWARD | 14,227 | — | — |
| May 18, 2026 | BAUM CHARLES M | Director | AWARD | 9,366 | — | — |
| May 18, 2026 | DiRocco Derek | Director | AWARD | 9,366 | — | — |
| May 18, 2026 | Palani Santhosh | Director | AWARD | 9,366 | — | — |
| May 18, 2026 | Magovcevic-Liebisch Ivana | Director | AWARD | 9,366 | — | — |
| May 18, 2026 | Shacham Sharon | Director | AWARD | 9,366 | — | — |
| May 18, 2026 | TOMSICEK MICHAEL JOHN | Director | AWARD | 9,366 | — | — |
| May 18, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | AWARD | 9,366 | — | — |
| May 14, 2026 | Miller Mary | Chief Legal Officer | TAX W/H | 184 | $1.92 | $353.28 |
| May 14, 2026 | Peterson Katharine | Chief Accounting Officer | TAX W/H | 99 | $1.92 | $190.08 |
| May 14, 2026 | Gamelin Erick | Chief Development Officer | TAX W/H | 404 | $1.92 | $775.68 |
| May 14, 2026 | Devroe Eric | Chief Operating Officer | TAX W/H | 613 | $1.92 | $1.2K |
| May 14, 2026 | Blume-Jensen Peter | President and CEO | TAX W/H | 1,253 | $1.92 | $2.4K |
| Apr 22, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | AWARD | 3,888,888 | $1.80 | $7.0M |
| Apr 17, 2026 | Miller Mary | Chief Legal Officer | TAX W/H | 558 | $1.78 | $993.24 |
| Mar 1, 2026 | Peterson Katharine | Chief Accounting Officer | AWARD | 31,900 | — | — |
| Mar 1, 2026 | Mirza Mansoor Raza | Chief Medical Officer | AWARD | 174,068 | — | — |
| Mar 1, 2026 | Miller Mary | Chief Legal Officer | AWARD | 129,760 | — | — |
| Mar 1, 2026 | Levy Adam D. | Chief Financial Officer | AWARD | 132,925 | — | — |
| Mar 1, 2026 | Gamelin Erick | Chief Development Officer | AWARD | 94,946 | — | — |
| Mar 1, 2026 | Devroe Eric | Chief Operating Officer | AWARD | 186,728 | — | — |
| Mar 1, 2026 | Blume-Jensen Peter | President and CEO | AWARD | 417,210 | — | — |
| Feb 21, 2026 | Blume-Jensen Peter | President and CEO | TAX W/H | 14,265 | $1.53 | $21.8K |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 2.5/10.
Historical analyst distribution (last covering-analyst action Jan 2026): 93% buy across 14 analysts — 4 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$11.50 mean target (Jan 2026)
$7.00 Low
$19.00 High
| Metric | Value |
|---|---|
| Current Price | $1.48 |
| Target Low | $7.00 |
| Target Mean | $11.50 |
| Target Median | $10.50 |
| Target High | $19.00 |
| # Analysts | 6 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.50 | $-0.55 | $-0.44 | 9.6% | +9.1% | 3↑ 2↓ | $0.0B | 0.0% | 7 |
| Next Q 2026-09-30 |
$-0.52 | $-0.59 | $-0.49 | -10.9% | -0.6% | 2↑ 3↓ | $0.0B | 0.0% | 7 |
| Current FY 2026-12-31 |
$-2.07 | $-2.50 | $-1.68 | -2.3% | +0.1% | 3↑ 2↓ | $0.0B | 0.0% | 7 |
| Next FY 2027-12-31 |
$-1.95 | $-2.61 | $-1.11 | 5.6% | -4.8% | 3↑ 1↓ | $0.0B | 0.0% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.497 | |
| 7d ago | $-0.497 | |
| 30d ago | $-0.547 | +0.050 |
| 60d ago | $-0.547 | +0.050 |
| 90d ago | $-0.506 | +0.009 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jan 9, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 4 | 9 | 2 | 0 | 0 | 87% | |
| Mar 1, 2026 | 4 | 9 | 2 | 0 | 0 | 87% | |
| Feb 1, 2026 | 4 | 9 | 2 | 0 | 0 | 87% | |
| Jan 1, 2026 | 4 | 9 | 2 | 0 | 0 | 87% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
60°
Warm
Bearish
Neutral
Bullish
1 mentions
1 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 7, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Insider Buys/Sells - AI Slop Scan
▲ 7
💬 2
⚡ 0.0
May 20, 2026
earnings_calendar
ACRV Q1 2026 Earnings Scheduled — 2026-05-20
May 15, 2026
other
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
<p>WATERTOWN, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical st
May 13, 2026
earnings
Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts
<p align="center"><em>The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update
Apr 17, 2026
other
Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities
<p align="center"><em>Potent preclinical efficacy with durable immune memory observed in combinations of either ACR-368 or ACR-2316 with anti-PD-L1 an
Apr 15, 2026
other
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
<p>WATERTOWN, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical
Mar 26, 2026
earnings_calendar
ACRV Q4 2025 Earnings After Market Close — 2026-03-26
Mar 19, 2026
earnings
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
<p align="center"><em>Maturing data from the ongoing registrational intent Phase 2b ACR-368 study showed a confirmed overall response rate (cORR) of 5
Mar 17, 2026
routine
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors
<p align="center"><em>ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (T